Impact of Pioglitazone, Metformin and the Combination of Both on Cardiovascular Risk in Insulin-Treated Patients With Type 2 Diabetes - The PIOcomb Study.
Phase of Trial: Phase IV
Latest Information Update: 11 Aug 2013
At a glance
- Drugs Metformin (Primary) ; Pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Acronyms PIOcomb
- Sponsors Takeda Pharma
- 10 Jun 2017 Biomarkers information updated
- 28 Apr 2012 Planned number of patients changed from 132 to 300 as reported by EudraCT.
- 28 Apr 2012 Additional trial location (Austria) identified as reported by EudraCT.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History